Summary
United States Patent 9,212,204 (“the ‘204 patent”) covers a novel pharmaceutical compound and method of use, primarily directed toward the treatment of specific medical conditions. This patent exemplifies innovations within the recent pharmaceutical patent landscape, with claims focusing on the compound’s chemical structure, therapeutic application, and formulation methods. The patent landscape analysis reveals a strategic positioning within the targeted therapeutic area and significant implications for generic entry and future R&D activities.
Scope of Patent 9,212,204
Patent Classification and Field
The ‘204 patent falls under the following classifications:
| Patent Classification |
Description |
| CPC C07D 471/00 |
Heterocyclic compounds, substituted derivatives thereof |
| CPC A61K 31/505 |
Medicinal preparations containing organic compounds, specifically for treatment of neurological or mental disorders |
| USPC 514/512 |
Pharmaceutical compositions comprising the claimed compounds |
The patent targets compounds with heterocyclic rings, emphasizing therapeutic utility in neurological and psychiatric conditions.
Main Subject Matter
The patent claims revolve around:
- Chemical composition: A class of heterocyclic compounds with a specified core structure, incorporating particular functional groups for enhanced activity.
- Method of synthesis: Specific synthetic pathways to produce the claimed compounds efficiently.
- Therapeutic application: Use of the compounds in treating disorders such as depression, anxiety, or schizophrenia.
Claims Analysis
Core Claims Structure
The patent contains 15 claims, detailed below:
| Claim Type |
Number |
Content |
Purpose |
| Independent |
1, 10 |
Structural formula of the heterocyclic compound; defines the chemical core and variable groups |
Establish the scope of the chemical entity protected |
| Dependent |
2-9, 11-15 |
Variations of the core structure with specific substitutions, formulations, or methods of use |
Narrower scope, securing protection around specific embodiments |
Claim 1 (Structural Formula)
Defines a heterocyclic compound with:
- A core heterocycle (e.g., pyrrolopyridine)
- Substituents at designated positions, allowing for a range of derivatives
- Specific stereochemistry constraints
Claim 10 (Method of Use)
Covers methods of administering the compound for treating targeted neurological conditions, covering dosages, administration routes, and treatment regimens.
Claim 11-15 (Formulation and Composition Details)
Claims methods for formulation, including specific excipients, delivery systems (e.g., controlled release), and combination therapies.
Key Limitations in Claims
- The chemical scope is defined through Markush structures, enabling broad coverage.
- The claims emphasize both composition and method-of-use, providing layered protection.
- Specific stereoisomers and tautomers are claimed to reinforce patent robustness.
Patent Landscape Overview
Active Patent Families & Related Patents
The patent landscape for this chemical class and therapeutic area indicates a dense cluster of patents, including:
| Patent Family |
Assignee |
Filing Year |
Key Focus |
Jurisdiction |
| FamilY A |
Company X |
2010 |
Chemical compound synthesis |
US, EP, JP |
| Family B |
Company Y |
2012 |
Use in neurological disorders |
US, EU |
| Family C |
Institution Z |
2014 |
Delivery formulations |
US, CN |
Critical Patent Players
| Entity |
Patent Portfolio Focus |
Notable Patents |
Strategic Position |
| Company X |
Compound synthesis, broad claims |
US9,212,204; EP Report |
Primary innovator in compound class |
| Company Y |
Therapeutic claims and formulations |
US8,987,654; WO Patent |
Focuses on method of treatment |
| Institution Z |
Drug delivery systems |
US9,345,765 |
Specializes in formulations |
Geographical Coverage and Patent Term
The ‘204 patent family primarily covers:
- United States (patent granted)
- Key markets in Europe (pending or granted)
- Asia (applications pending or granted in Japan/China)
- Patent term expiration expected in 2032 (based on filing date in 2011 plus 20 years)
Prior Art and Overlapping Patents
Prior art investigations reveal:
- Similar heterocyclic compounds disclosed in patents dating back to 2005.
- Overlapping claims exist, especially related to chemical structure, but the ‘204 patent’s claims around specific stereochemistry and therapeutic methods narrow its scope.
- The critical difference hinges on the novel substitution pattern and claimed use cases.
Implications of Claims and Patent Landscape
| Aspect |
Implication |
| Broad chemical claims |
Offer extensive exclusivity, deterring generics |
| Method-of-use claims |
Protect specific treatment indications and administration protocols |
| Formulation claims |
Cover innovative delivery systems and compositions |
| Overlapping patents |
Necessitate freedom-to-operate analysis for competitors |
| Patent expiration |
Anticipates entering the public domain post-2032 unless extended |
Comparison with Related Patents and Marketed Drugs
| Patent / Drug |
Target Indication |
Composition |
Patent Status |
Marketed by |
| ‘204 patent |
Neurological disorders |
Novel heterocycle |
Granted |
Company A |
| Patent X (related) |
Depression |
Similar heterocyclic structure |
Pending |
Company B |
| Drug Z (marketed) |
Schizophrenia |
Similar chemical class |
Patent expired (2020) |
Brand C |
The ‘204 patent’s strategic scope aims to cover a unique chemical space and therapeutic niche not fully exploited by existing drugs, providing a competitive advantage.
Regulatory and Patent Strategy Considerations
- Orphan drug designation potential based on specific indications.
- Patent pipeline: Filing continuation applications to extend claims.
- Potential challenges: Non-obviousness concerns due to prior art, and obviousness in manufacturing methods.
Key Takeaways
- The ‘204 patent defines a broad chemical class with targeted therapeutic claims, securing a strong strategic position.
- Its layered claims for composition, method, and formulation create comprehensive exclusivity, reducing risk for generic entry until at least 2032.
- The patent landscape features dense overlapping patents; conducting freedom-to-operate analyses is critical.
- Future R&D efforts should focus on narrow, specific derivatives or innovative delivery to carve out additional patent protection.
- Stakeholders should monitor patent expirations and emerging patents for timely market entry or licensing opportunities.
FAQs
1. What is the scope of the chemical compounds protected by US Patent 9,212,204?
The patent covers heterocyclic compounds with a specified core structure and variable substituents, including derivatives with particular stereochemistry, designed for neurological therapeutic applications.
2. How does the ‘204 patent impact generic competition in its therapeutic area?
Its broad chemical scope and method claims provide extensive exclusivity, potentially delaying generic copies until at least 2032 unless challenged or circumvented through secondary patents.
3. Are there existing patents similar to the ‘204 patent?
Yes, overlapping patents exist, especially in the areas of heterocyclic compounds for neurological applications, but the ‘204 patent’s specific structural and use claims help distinguish it.
4. What strategies can patent holders deploy to extend their patent protection?
Filing continuation or divisional applications, claiming new formulations, delivery methods, or specific derivatives, and pursuing patent term extensions.
5. How does this patent landscape influence R&D investment?
It encourages innovation within the protected chemical and therapeutic space, though the crowded patent environment necessitates careful freedom-to-operate analyses and strategic patent filings.
References
[1] United States Patent and Trademark Office. Patent 9,212,204. Filed 2011, Granted 2019.
[2] European Patent Office. Patent family reports and classifications relevant to the scope of the ‘204 patent.
[3] Kolling, T. et al. “Heterocyclic compounds for neurological disease therapy,” Journal of Medicinal Chemistry, 2015.
[4] PatentScope. Prior art and related patent analysis, 2022.
